Pfizer delays drug launch pending DEA classification

06/14/2005 |

Pfizer says it is almost ready to launch Lyrica for treating epilepsy, nearly a year after the FDA approved the medicine. The company is awaiting a decision from the Drug Enforcement Administration, which will dictate the level of controlled substance Lyrica, intended for relieving nerve pain from diabetes and shingles, will be classified as.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC